KBLB Kraig Biocraft Laboratories Inc.

Kraig Biocraft Laboratories Secures $4 Million Dollars of Expansion Capital

Kraig Biocraft Laboratories Secures $4 Million Dollars of Expansion Capital

ANN ARBOR, Mich., March 26, 2021 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $4 million dollars of expansion capital. This financing significantly strengthens the Company’s balance sheet and supports its progress in the commercialization and sale of recombinant spider silk.

“This is a major financial milestone for Kraig. For many years we have operated on a shoestring budget, building a solid foundation with our spider silk production system. We are now prepared to reap the rewards of that careful investment with opportunities to put this capital to work building materials, products and brands,” said CEO and Founder, Kim Thompson.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Except as required by law, the Company does not undertake any responsibility to revise or update any forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495



EN
26/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kraig Biocraft Laboratories Inc.

 PRESS RELEASE

Kraig Biocraft Laboratories Signs Landmark Collaborative Agreement wit...

Kraig Biocraft Laboratories Signs Landmark Collaborative Agreement with Government Agency in Southeast Asia to Advance Spider Silk Production ANN ARBOR, Mich., July 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced the formal signing of a multi-year agreement with a government agency in Southeast Asia to support the scale-up of its recombinant spider silk production. This agreement is the result of many years of groundwork by Kraig Labs and marks a significant step in the Co...

 PRESS RELEASE

Kraig Biocraft Laboratories Successfully Completes Lab-to-Field Transi...

Kraig Biocraft Laboratories Successfully Completes Lab-to-Field Transition for Three New Spider Silk Production Strains Newly Deployed Strains Deliver Strong Performance in Initial Field Rearing Cycles, Paving the Way for Accelerated Deployment of Next-Generation Transgenics ANN ARBOR, Mich., July 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces the successful completion of the first rearing cycles for its three newest recombinant spider silk production strains. These newly deve...

 PRESS RELEASE

Kraig Biocraft Laboratories Nears Strategic Three-Year Government Coll...

Kraig Biocraft Laboratories Nears Strategic Three-Year Government Collaboration to Expand Recombinant Spider Silk Production ANN ARBOR, Mich., July 18, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it is finalizing a significant three-year collaborative agreement with a key government agency in Southeast Asia to expand the scale and security of its recombinant spider silk manufacturing platform. This landmark agreement, expected to be signed before the end of July, marks the ...

 PRESS RELEASE

Kraig Biocraft Laboratories Announces Second Production Facility, Thre...

Kraig Biocraft Laboratories Announces Second Production Facility, Three Advanced Spider Silk Strains, and New Diapausing System New Architecture lays foundation for Higher Output, continuous Batch Production, and prepares Company for Spider Silk delivery to European based Global Luxury Market Leader ANN ARBOR, Mich., July 14, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company", “Kraig”, or "Kraig Labs"), a world leader in spider silk technology*, announces the addition of a second parallel production facility, three new advanced spider silk strains, and t...

 PRESS RELEASE

Kraig Biocraft Laboratories Announces Senior Management Trip to Southe...

Kraig Biocraft Laboratories Announces Senior Management Trip to Southeast Asia to Oversee Expansion of Spider Silk Production ANN ARBOR, Mich., June 10, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that senior management will travel to Southeast Asia this week to oversee the continued expansion of the Company's recombinant spider silk production operations. This strategic visit is designed to support and accelerate the Company’s 2025 production scale-up. In addition to reinforc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch